Weiner, Honored for Research on Targeted Cancer Therapy, Named to Fox Chase Cancer Center's G. Morris Dorrance Jr. Endowed Chair
PHILADELPHIA (June 24, 2002)-Fox Chase Cancer Center recently celebrated first-time appointments to three new faculty chairs, each endowed with gifts totaling $1.5 million. The first to hold the new G. Morris Dorrance Jr. Endowed Chair is Fox Chase medical oncology chairman Louis M. Weiner, M.D., a longtime resident of Elkins Park, Pa., who is now moving to Rydal, Pa.
Contributions from friends, family members and colleagues on the board endowed the chair in Dorrance's honor. A resident of Villanova, Pa., for many years, Dorrance served as the first chairman of the Fox Chase board of directors from 1974 to 1995 and remains a member of the board.
Weiner specializes in treating patients with advanced gastrointestinal cancers as well as conducting research on innovative cancer therapies. He is also a professor of medicine at Temple University School of Medicine and chief of medical oncology for the joint Fox Chase-Temple Cancer Center based at Temple University.
"Through his work here," said Fox Chase president Robert C. Young, M.D., "Lou has forged an international reputation for his expertise on targeted therapies for cancer and antibody engineering. His laboratory and clinical research focuses on new treatment approaches that mobilize the patient's immune system to fight cancer."
These therapies use biologic response modifiers produced by the immune system and monoclonal antibodies-laboratory-crafted proteins designed to recognize specific cancer cells. Weiner has developed and tested two-way, "bispecific" antibodies and related proteins that not only recognize and bind to cancer cells but also stimulate cells of the immune system to attack these targets.
In 1997 Janssen Pharmaceutica Research Foundation's honored Weiner with its Award for Outstanding Contributions to the Field of Receptor-Targeted Therapy. He also received the 2001 American Cancer Society Southeast Region Scientific Research Award.
He is Fox Chase's principal investigator for the Eastern Cooperative Oncology Group, a national study group that conducts clinical trials. He chairs its committee on biologic response modifiers and its translational research committee.
Weiner received his M.D. from Mount Sinai School of Medicine in New York City. He joined the Fox Chase staff in 1984, after clinical and research fellowships at Tufts University School of Medicine. He directed the Fox Chase's immunotherapy program and developed and directed the medical oncology fellowship program before becoming chairman of the medical oncology department in 1994.
In thanking Fox Chase for his new appointment, Weiner called the endowed chair "a vessel through which the traditions and values of our institution flow. I am particularly humbled to hold the Dorrance chair, which bears a name of paramount significance in the history of Fox Chase."
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Jeremy Moore at 215-728-2700.